Elson Vidal

Gastroenterologista & Hepatologista

[Jasmohan Bajaj @JasmohanBajaj]

A🌎study of >2500 #cirrhosis inpts➡️no link b/w #rifaximin & drug-resistant #infections
Done w #CLEARED consortium
🔑#rifaximin➡️useful for #HE
✅real-world evidence before changing practice!

@CMH_journal https://t.co/BUbvyG8Wvd
builds on @AGA_Gastro https://t.co/QSMObg68R7

[Uma Mahadevan @UmaMahadevanIBD]

Exciting @DDWMeeting IBD LATE BREAKER. Fuzion trial shows benefit of guselkumab for fistulizing Crohn’s disease. @PeyrinBiroulet

[Zeinab Bakhshi MD @z_bakhshiii]

📊 #DDW2026 TRIDENT-UC study
In bio-experienced #UC patients:
👉 Upadacitinib > Tofacitinib > Ustekinumab
across:
✔️ Steroid-free clinical remission
✔️ Biochemical remission
✔️ Endoscopic remission
⏱️ Consistent at 16 & 52 weeks
#GITwitter @DDWMeeting #IBD

[Icahn School of Medicine at Mount Sinai @IcahnMountSinai]

A landmark review from the Icahn School of Medicine at Mount Sinai, published in Cell, offers one of the clearest roadmaps to date for understanding and treating liver cancer—one of the deadliest cancers worldwide.

Led by Josep M. Llovet, MD, PhD, and Daniela Sia, PhD, the study applies the influential “Hallmarks of Cancer” framework to liver tumors, linking key biological drivers of disease to emerging treatment strategies, including immunotherapy and precision medicine. The work highlights how different forms of liver cancer develop and identifies critical vulnerabilities—particularly in bile duct cancers, where nearly half of tumors harbor targetable genetic alterations.

By bridging decades of research with clinical application, this review provides a powerful framework to guide more personalized treatment approaches and accelerate the development of new therapies for patients.

Read the full study: https://t.co/AgWwLkHFgg

[UEGJ @UEGJournal]

👩‍👧Maternal #MASLD increases risk of serious infections in offspring

Swedish nationwide cohort:
🔸 Overall risk ↑ (aHR 1.81)
🔸 Highest in infancy (aHR 3.11)
🔸 Risk persists up to 31 yrs

📖 #OpenAccess 👉 https://t.co/R9mWwwXvd5

@my_ueg

[Scott Isaacs @scottisaacsmd]

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.
https://t.co/xnMLLYA9bR

[Scott Isaacs @scottisaacsmd]

Using noninvasive tests to stage fibrosis opens the door to truly personalized MASLD and MASH care, allowing us to match lifestyle, incretin based therapies, resmetirom and standard cirrhosis management to each patient’s fibrosis stage, enabling an approach tailored to liver disease severity.
https://t.co/DVMslWhEFl

[CGH @AGA_CGH]

🧬 Who should be treated for MASLD? This Hepatology original research article explores a practical criteria set—combining FIB‑4, transient elastography, diabetes, and overweight status—to better guide treatment decisions. 📖✨

Read More: https://t.co/izzSVcv3WT

[Dr Meenakshi Jain MD, FRCP, FICN @MeenakshiJainMD]

If you enjoyed this please ♥️and 🔁the first post
https://t.co/wBGD4SNvdE

[Elson Vidal @elsonvidal]

Lancet paper released on medicinal cannabis effectiveness https://t.co/0bGQVkwzBE via @AMA

[Ramon Bataller @rabataller]

Auto-Brewery Syndrome (ABS): the gut microbiome produces alcohol → patients can be intoxicated without drinking.

Fascinating presentation by Dr. Bernd Schnabl at #SLDSummit:

🦠 Gut → ethanol-producing bacteria
🍞 Carbs → endogenous alcohol

Diagnosis tricky but real impact

[Marat Fudim, MD MHS @FudimMarat]

🧵1. HFpEF (heart failure w/ preserved ejection fraction) & MASLD (metabolic dysfunction-associated steatotic liver disease) are rising together with obesity/metabolic syndrome. Once siloed, now reflect shared systemic metabolic dysfunction driving disease in both heart & liver.

[Scott Isaacs @scottisaacsmd]

Meta-analysis finds that metabolic bariatric surgery delivers the largest and most durable weight loss, but semaglutide and tirzepatide rival surgery short term with far fewer serious adverse events.
https://t.co/Jr780MQOfH

[Jasmohan Bajaj @JasmohanBajaj]

Both #PCABs & #PPI suppress acid but have different PK & #microbial impact....do they impact #cirrhosis outcomes differently? YES
In Asia-Pacific @TriNetX w many sensitivity analyses, #Vonoprazan ➡️ better outcomes vs PPI
@AmJGastro @nilangpatel et al⤵️
https://t.co/MeDhajOsdT

[BCLC GROUP @BCLC_group]

Final print of BCLC 2025 available at https://t.co/7aWaO8VFmA A team effort by BCLC members and external experts. Incorporation of CUSE concepts into the MTBoard allows personalised recommendations @hospitalclinic @idibaps @EASLnews @ILCAnews @AEEHLiver @ContraCancerEs

[Elson Vidal @elsonvidal]

@CataPaul2 @grok onde estão expostas?

[Scott Isaacs @scottisaacsmd]

Extrahepatic manifestations of #MASLD.
https://t.co/8XoDaHSj49

[Jana G Hashash, MD, MSc @JHashashMD]

All 🫵 you need to know 🤓about 🩺🩻 evaluation and management 🩼💊💉 of Inpatient #IBD in @AmerGastroAssn @AGA_Gastro

✅Acute severe colitis

✅Small bowel obstruction

✅Intra-abdominal abscess

✅Perinal disease

‼️🚨DVT prophylaxis is critical🚨‼️

https://t.co/aSO4WSwa34

[American Gastroenterological Association (AGA) @AmerGastroAssn]

Best practices for managing ascites, volume overload & hyponatremia in cirrhosis.
Our new CPU in @AGA_Gastro shares 1️⃣3️⃣ evidence-based tips to support clinical decision-making.
Read more here: https://t.co/VT2rL72eIJ
@orman_md @BrettEFortuneMD @AsraniSumeet
#GITwitter

[Elson Vidal @elsonvidal]

Say Cheese! The Unlikely Origins of Ultrasound Elastography https://t.co/rG45AMTAXL